Prescribing Information
Adverse event reporting is available on the above link or at the bottom of the page
This is intended for HCPs practising in the United Kingdom only.
Simulate how much you can save by switching from NovoRapid® 100 units/ml to Trurapi® 100 units/ml (prefilled pen/cartridge)
- Average dose per patient is based on the total Net Ingredient Cost from ePACT2 (MAT Sep 2020) for NovoRapid, divided by the total number of patients estimated to be on treatment for each insulin (IQVIA Longitudinal Patient Data)1
- Cost differences for a cohort of patients were based on an assumption that the split of cartridge:prefilled pens is the same as the ratio of cartridge:prefilled pen use nationally, according to ePACT2 data from the period October 2019 - September 20201
- Where a product is listed generically in ePACT, e.g. insulin aspart 100 units/mL cartridge, this could potentially have been dispensed as Novorapid or as Fiasp but it was assumed it is NovoRapid1
- Calculation on patients using NovoRapid 100 units/ml were based on a national market share of 42:56:2 split (cartridge:FlexPen:FlexTouch use)1
- Only insulin costs (NHS list price) were included in this model. Any local discounts/rebates and the cost of implementing a switch program were not taken into account
- The model assumes dose equivalence between products - when transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended2
